Case report : Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton's agammaglobulinemia
Copyright © 2022 Rise, Touborg, Lundsted, Dalager-Pedersen and Mogensen..
Despite several reports and small case series on the disease course of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI), including X-linked agammaglobulinemia (XLA), this topic remains incompletely described. Here we present the case of a 38-year-old unvaccinated man with XLA, who acquired SARS-CoV-2 infection and experienced a protracted disease course with 47 days of SARS-CoV-2 positivity, critical COVID-19 with respiratory insufficiency necessitating intensive care and ventilatory support, and prompting repeated intensified treatments with remdesivir, dexamethasone, and monoclonal antibodies to eventually control infection. We describe the disease course and treatment and review the current literature on COVID-19 susceptibility and evidence for vaccine efficacy in patients with XLA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 13(2022) vom: 20., Seite 1057065 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rise, Nina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bruton’s agammaglobulinemia |
|---|
| Anmerkungen: |
Date Completed 16.12.2022 Date Revised 21.12.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2022.1057065 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350175888 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350175888 | ||
| 003 | DE-627 | ||
| 005 | 20231226205702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.1057065 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350175888 | ||
| 035 | |a (NLM)36505407 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rise, Nina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Case report |b Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton's agammaglobulinemia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Rise, Touborg, Lundsted, Dalager-Pedersen and Mogensen. | ||
| 520 | |a Despite several reports and small case series on the disease course of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI), including X-linked agammaglobulinemia (XLA), this topic remains incompletely described. Here we present the case of a 38-year-old unvaccinated man with XLA, who acquired SARS-CoV-2 infection and experienced a protracted disease course with 47 days of SARS-CoV-2 positivity, critical COVID-19 with respiratory insufficiency necessitating intensive care and ventilatory support, and prompting repeated intensified treatments with remdesivir, dexamethasone, and monoclonal antibodies to eventually control infection. We describe the disease course and treatment and review the current literature on COVID-19 susceptibility and evidence for vaccine efficacy in patients with XLA | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Bruton’s agammaglobulinemia | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a inborn error of immunity | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a viral Evolution | |
| 700 | 1 | |a Touborg, Toke |e verfasserin |4 aut | |
| 700 | 1 | |a Lundsted, Ditte Helene |e verfasserin |4 aut | |
| 700 | 1 | |a Dalager-Pedersen, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Mogensen, Trine H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022) vom: 20., Seite 1057065 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:20 |g pages:1057065 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.1057065 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 20 |h 1057065 | ||